Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children

  • 143 Accesses

  • 43 Citations

Abstract

In this study we assessed the prevalence of fat redistribution and metabolic disorders in a population of HIV-infected children on antiretroviral treatment. To make associations with epidemiological parameters, clinical-immune status, viral load and highly active antiretroviral therapy (HAART), we performed a cross-sectional study in HIV-infected children. Epidemiological parameters (age, sex, family history), clinical and immune status, viral load, and duration of antiretroviral treatment (ART) and HAART, including protease inhibitors, were recorded. Presence of clinical signs of fat redistribution and lipid, glucose and lactic acid levels were evaluated. A total of 56 HIV-infected children, including 30 boys (54%), aged between 21 months and 18 years (mean 9.5 years) were studied. In all, 49 patients (87.5%) were receiving ART (mean duration 4 years) and 43 (77%) were receiving HAART (mean duration 3.6 years). Fat redistribution or lipodystrophy was present in 14 patients (25%); seven had lipohypertrophy (12.5%), two lipoatrophy (3.5%) and five a mixed pattern (8.9%). Fat redistribution was higher in children older than 11 years (50%). Of the lipodystrophic patients, 71.4% presented hypertriglyceridaemia (>130 mg/dl) and 57% hypercholesterolaemia (>180 mg/dl). We found significant associations between lipodystrophy and age, ART and HAART duration and hypertriglyceridaemia ( P <0.001, 0.002, 0.016 and <0.001, respectively), but no significant association with sex, family history, clinical or immune status and viral load. Conclusion:The prevalence of lipodystrophy was 25% (95% confidence interval 14.8–34.6) with lipohypertrophy being the commonest pattern. Clinical fat redistribution was significantly associated with older age, duration of antiretroviral treatment and highly active antiretroviral therapy and hypertriglyceridaemia.

This is a preview of subscription content, log in to check access.

Abbreviations

ART :

antiretroviral treatment

CDC :

Center for Disease Control

HAART :

highly active antiretroviral treatment

LPDS :

lipodystrophy syndrome

NRTI :

nucleoside reverse transcriptase inhibitors

NNRTI :

non-nucleoside reverse transcriptase inhibitors

PI :

protease inhibitor

References

  1. 1.

    Amaya R, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW (2002) Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 21: 405–410

  2. 2.

    Arpadi SM, Cuff P, Horlick MN, Kotler DP (1999) Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment. AIDS 13: 2312–2313

  3. 3.

    Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP (2001) Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ lymphocyte count and CD4+ lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 27: 30–34

  4. 4.

    Babl FE, Regan AM, Pelton SI (1999) Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet 353: 1243–1244

  5. 5.

    Benson J, Mc Ghee K, Coplan P, Grundfeld C, Robertson M, Brodovicz KG, Slater E (2000) Fat redistribution in indinavir treated patients with HIV infection: a review of postmarketing cases. J AIDS 25: 130–139

  6. 6.

    Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ (2003) Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J 22: 463–465

  7. 7.

    Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, Di Natale B, Vigano A (2001) Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 15: 2415–2422

  8. 8.

    Cánoves L (2002) Psicopatologías en el síndrome de lipodistrofia. In: Polo Rodrigez R (ed) Manual de nutrición y SIDA. Nilo, Madrid, pp 586–605

  9. 9.

    Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Abnormal fat distribution and use of protease inhibitors. Lancet 351: 1736

  10. 10.

    Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51–F58

  11. 11.

    Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093–2099

  12. 12.

    Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361: 726–735

  13. 13.

    Centers for Disease Control and Prevention (1994) Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 43: 1–10

  14. 14.

    Cossarizza A, Mussini C, Vigano A (2001) Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? Bioessays 23: 1070–1080

  15. 15.

    Cossarizza A, Pinti M, Moretti L, Bricalli D, Bianchi R, Troiano L, Fernandez MG, Balli F, Brambilla P, Mussini C, Vigano A (2001) Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis 185: 299–305

  16. 16.

    Cossarizza A, Troiano L, Mussini C (2002) Mitochondria and HIV infection: the first decade. J Biol Regul Homeost Agents 16: 18–24

  17. 17.

    European Paediatric Lipodystrophy Group (2004) Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 18: 1443–1451

  18. 18.

    Galli M, Veglia F, Angarano G, Santambrogio S, Meneghini E, Gritti F (2003) Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at high risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 34: 58–61

  19. 19.

    Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D’Agostino RB, Grinspoon S (2001) Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32: 130–139

  20. 20.

    Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, Levy-Marchal C (2000) Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 14: 2123–2128

  21. 21.

    Leonard EG, McComsey GA (2003) Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 22: 77–84

  22. 22.

    Martinez E, Gatell JM (1999) Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr Opin Infect Dis 12: 13–19

  23. 23.

    Martinez E, Bianchi L, García-Viejo MA, Bru C, Gatell JM (2000) Sonographic assessment of regional fat in HIV-infected persons. Lancet 356: 1412–1413

  24. 24.

    Martinez E, García-Viejo MA, Blanch J, Gatell JM (2001) Lipodystrophy syndrome in patients with HIV infection:quality of life issues. Drug Safety 24: 157–166

  25. 25.

    Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Philips A, Gatell JM (2001) Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357: 592–598

  26. 26.

    McComsey G, B.N, Ma Jen-Fu, Rathore M, Alvarez A (2003) Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the first pediatric switch study. Pediatrics 111: 275–281

  27. 27.

    McComsey G, Leonard E (2004) Metabolic complications of HIV therapy in children. AIDS 18: 1753–1768

  28. 28.

    Miller TL (2000) Nutrition in paediatric human immunodeficiency virus infection. Proc Nutr Soc 59: 155–162

  29. 29.

    Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A (2001) Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 15: 1823–1829

  30. 30.

    Narciso P, Tozzi V, D’Offizi G, De Carli G, Orchi N, Galati V, Vincenzi L, Bellagamba R, Carvelli C, Puro V (2001) Metabolic and morphologic disorders in patients treated with highly active antiretroviral therapy since primary HIV infection. Ann N Y Acad Sci 946: 214–222

  31. 31.

    Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A (2001) Sex differences in HAART-associated dyslipidaemia. AIDS 15: 725–734

  32. 32.

    Polo Rodriguez R (2002) Manual de Nutrición y SIDA, 3rd edn. Nilo, Madrid

  33. 33.

    Saint-Marc T, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL (2002) Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14: 37–49

  34. 34.

    Seidell JC, van der Kooy K (1990) Imaging techniques for measuring adipose tissue distribution: a comparison between computed tomography and 1.5 T magnetic resonance. Am J Clin Nutr 51: 953–957

  35. 35.

    Van Rossum AM, Fraaij JP, de Groot R (2002) Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2: 93–102

  36. 36.

    Wedekind CA, Pugatch D (2001) Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy 21: 861–866

  37. 37.

    Yoshizumi T, Nakamura T, Yamane N, Islam AH, Menju M, Yamasaki K, Arai T, Kotami K, Funahashi T, Yamashita S, Matsuzawa Y (1999) Abdominal fat: standardized technique for measurement at CT. Radiology 211: 283–286

Download references

Author information

Correspondence to María Isabel De José Gómez.

Additional information

Presented in part at the XIV International AIDS Conference in Barcelona (Spain), July 2002

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sánchez Torres, A.M., Munoz Muniz, R., Madero, R. et al. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 164, 271–276 (2005). https://doi.org/10.1007/s00431-004-1610-y

Download citation

Keywords

  • Children
  • Highly active antiretroviral treatment
  • HIV infection
  • Hypertriglyceridaemia
  • Lipodystrophy